131 related articles for article (PubMed ID: 21270824)
1. RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells.
Kupas V; Weishaupt C; Siepmann D; Kaserer ML; Eickelmann M; Metze D; Luger TA; Beissert S; Loser K
J Invest Dermatol; 2011 Apr; 131(4):944-55. PubMed ID: 21270824
[TBL] [Abstract][Full Text] [Related]
2. Pulling RANK: are some melanoma cells more malignant than others?
Shackleton M
J Invest Dermatol; 2011 Apr; 131(4):814-6. PubMed ID: 21407234
[TBL] [Abstract][Full Text] [Related]
3. Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.
Gray ES; Reid AL; Bowyer S; Calapre L; Siew K; Pearce R; Cowell L; Frank MH; Millward M; Ziman M
J Invest Dermatol; 2015 Aug; 135(8):2040-2048. PubMed ID: 25830652
[TBL] [Abstract][Full Text] [Related]
4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
5. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
6. [Bone metastasis and RANKL].
Nakashima T
Clin Calcium; 2014 Aug; 24(8):1201-8. PubMed ID: 25065872
[TBL] [Abstract][Full Text] [Related]
7. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.
Santini D; Perrone G; Roato I; Godio L; Pantano F; Grasso D; Russo A; Vincenzi B; Fratto ME; Sabbatini R; Della Pepa C; Porta C; Del Conte A; Schiavon G; Berruti A; Tomasino RM; Papotti M; Papapietro N; Onetti Muda A; Denaro V; Tonini G
J Cell Physiol; 2011 Mar; 226(3):780-4. PubMed ID: 20857484
[TBL] [Abstract][Full Text] [Related]
8. Bone metastasis: can osteoclasts be excluded?
Martin TJ; Mundy GR
Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
[TBL] [Abstract][Full Text] [Related]
9. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
11. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
[TBL] [Abstract][Full Text] [Related]
12. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cancer cell migration and bone metastasis by RANKL.
Jones DH; Nakashima T; Sanchez OH; Kozieradzki I; Komarova SV; Sarosi I; Morony S; Rubin E; Sarao R; Hojilla CV; Komnenovic V; Kong YY; Schreiber M; Dixon SJ; Sims SM; Khokha R; Wada T; Penninger JM
Nature; 2006 Mar; 440(7084):692-6. PubMed ID: 16572175
[TBL] [Abstract][Full Text] [Related]
14. Infrared imaging of primary melanomas reveals hints of regional and distant metastases.
Wald N; Goormaghtigh E
Analyst; 2015 Apr; 140(7):2144-55. PubMed ID: 25574519
[TBL] [Abstract][Full Text] [Related]
15. Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients.
Crende O; Sabatino M; Valcárcel M; Carrascal T; Riestra P; López-Guerrero JA; Nagore E; Mandruzzato S; Wang E; Marincola FM; Vidal-Vanaclocha F
Am J Pathol; 2013 Jul; 183(1):69-82. PubMed ID: 23707237
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin K in melanoma invasion.
Quintanilla-Dieck MJ; Codriansky K; Keady M; Bhawan J; Rünger TM
J Invest Dermatol; 2008 Sep; 128(9):2281-8. PubMed ID: 18368130
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
Golden D; Saria EA; Hansen MF
J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
[TBL] [Abstract][Full Text] [Related]
18. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
19. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
20. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
